[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

USH328H - Purification of cephalosporins - Google Patents

Purification of cephalosporins Download PDF

Info

Publication number
USH328H
USH328H US06/696,430 US69643085A USH328H US H328 H USH328 H US H328H US 69643085 A US69643085 A US 69643085A US H328 H USH328 H US H328H
Authority
US
United States
Prior art keywords
carboxylic acid
oxacephalosporin
eluting
aqueous solution
macroporous polymeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US06/696,430
Inventor
Hiroaki Koizumi
Satoru Kawatake
Kanji Tokuyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Assigned to SHIONOGI & CO., LTD. reassignment SHIONOGI & CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: KAWATAKE, SATORU, KOIZUMI, HIROAKI, TOKUYAMA, KANJI
Application granted granted Critical
Publication of USH328H publication Critical patent/USH328H/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring

Definitions

  • This invention relates to a process for purifying oxacephalosporins useful as antibacterials. More specifically, it relates to a process for purifying oxacephalosporin carboxylic acids which comprises contacting an aqueous solution of the oxacephalosporin carboxylic acid (at pH lower than its pKa) with a macroporous polymeric adsorbent (specific gravity: higher than 1.05; and saturated adsorption capacity for cephalosporin C: larger than 60 mg/ml, i.e., more than 1.2 times as high as adsorbents reported in the literature to separate non-adsorbable contaminants therefrom, and then eluting it with an aqueous hydrophilic organic solvent to separate from non-eluting contaminants therefrom.
  • a macroporous polymeric adsorbent specifically gravity: higher than 1.05
  • saturated adsorption capacity for cephalosporin C larger than 60 mg/ml, i.e., more than 1.2 times
  • oxacephalosporins contaminants are removed by repeated extraction, precipitation, crystallization, adsorption by old type synthetic adsorbents (e.g., Amberlite XAD-2, XAD-4, XAD-7, XAD-8, Diaion HP-10, HP-20, HP-30, HP-40, and HP-50), elution, or the like in the work up.
  • old type synthetic adsorbents e.g., Amberlite XAD-2, XAD-4, XAD-7, XAD-8, Diaion HP-10, HP-20, HP-30, HP-40, and HP-50
  • the present inventors looked for a suitable method to promote efficiency of the purification and completed this invention for purifying it with a macroporous polymeric adsorbent (specific gravity: higher than 1.05; and saturated adsorption capacity for cephalosporin C: larger than 60 mg/ml, i.e., more than 1.2 times as high as adsorbent written in the citations).
  • the macroporous polymeric adsorbent of this invention (having specific gravity of higher than 1.05 and saturated adsorption capacity for cephalosporin C of larger than 60 mg/ml., i.e., more than 1.2 times as high as adsorbents written in the literatures) has no such defect, and it is suitable for purifying the unstable oxacephalosporin free carboxylic acids.
  • Typical nonionic macroporus polymeric adsorbents are Amberlite XAD-2000, a stylene divinylbenzene copolymer resin produced by Rohm and Haas Co., and Diaion SP-206 and SP-207, styrene divinylbenzene copolymer resins produced by Mitsubishi Chemical Industries Limited.
  • the oxacephalosporin to be purified by this invention is 1-dethia-1-oxa-3-cephem-4-carboxylic acid or its derivative having at least one carboxy and having acylamino at position 7 ⁇ , hydrogen or methoxy at position 7 ⁇ , and R or CH 2 R group at position 3 (here, R is hydrogen, halogen, alkyl, carbamoyl, carboxy, hydroxy, alkoxy, acyloxy, alkylthio, haloalkylthio, arylthio, heterocyclic thio, pyridinium, substituted pyridinium, or the like nucleophilic group).
  • the acyl in the acylamino is that of the amido side chain in the penicillin or cephalosporin chemistry.
  • the heterocyclic group is mono- or di-cyclic heterocyclic group having one or more hetero atom selected from nitrogen, oxygen, and sulfur and optionally substituted by alkyl or R-substituted alkyl.
  • the said parts may have R or other conventional substituent in the cephalosporin moiety.
  • the amount of the macroporous polymeric resin used in this invention (having specific gravity of higher than 1.05 and saturated adsorption capacity for cephalosporin C of larger than 60 mg/ml, i.e., more than 1.2 times as high as adsorbents written in the literatures) is preferably 5 to 100 times the weight of the feeding oxacephalosporin free carboxylic acid.
  • the concentration of the oxacephalosporin carboxylic acid is preferably 0.1 to 30 w/w %.
  • the solution contains no adsorption inhibiting substance (for example, an organic solvent) over the inihibiting concentration.
  • the operating temperature is preferably 0° to 50° C.
  • Adsorption is effected by contacting the aqueous solution of oxacephalosporin with the said macroporous polymer adsorbent by a conventional method (e.g., batch method, column method, or chromatographic method).
  • a conventional method e.g., batch method, column method, or chromatographic method.
  • the resin on which oxacephalosporin has been adsorbed is washed with a liquid which can wash out the non-adsorbable contaminants without eluting the desired substance.
  • a liquid which can wash out the non-adsorbable contaminants without eluting the desired substance.
  • Such liquid can be, for example, water, buffer solution, salt solution, aqueous surfactant solution, or the like.
  • a conventional method e.g., batch method, column method, chromatographic method, or gradient method
  • the washing can be continued until no impurity detectable in the effluents from the resin.
  • the preferable temperature is 0° to 50° C.
  • an aqueous organic solvent e.g., ester, ketone, alcohol, or ether, especially lower alkanol.
  • This may contain a substance for controlling eluting efficiency or independent of eluting (e.g., inorganic salt, acid, base, or cation surfactant).
  • This elution may be carried out in a conventional operation (e.g., batch method, column method, chromatographic method, or gradient method), preferably at 0° to 50° C. The eluting procedure is stopped when the objective material has been eluted and the non-eluting contaminants remain on the adsorbent.
  • the used adsorbent can be recovered for using again in a usual operation (with, e.g., aqueous sodium hydroxide, neutral or acidic methanol or isopropanol, or mixture of these).
  • the oxacephalosporin can be recovered from the effluents by a conventional operation (e.g., extraction, concentration, precipitation, crystallization, of lyophilization).
  • Each step of this invention can be carried out at room temperature or at 0° to 50° C. for 30 minutes to 50 hours.
  • the oxacephalosporin carboxylic acids produced by this invention with low energy consumption is highly pure and highly yielding.
  • a 0.11% crude latamoxef sodium i.e., 7 ⁇ -(2-p-hydroxyphenyl-2-carboxyacetamido)-3-(1-methyltetrazol-5-yl]thiomethyl-7 ⁇ -methoxy-1-dethia-1-dethia-1-oxa-3-cephem-4-carboxylic acid disodium salt
  • aqueous solution produced by hydrolyzing latamoxef dibenzhydryl ester with aluminum chloride and by removing organic solvents from the reaction mixture is adjusted pH to 1.5 with hydrochloric acid.
  • a nonionic macroporous polymeric adsorbent (Amberlite XAD-2000, a stylene-divinylbenzene copolymer adsorbent resin produced by Rohm and Haas Co.) (200 ml) is packed in 270 mm height in a glass tube which has 32 mm inside diameter and 350 mm length.
  • the said solution (2780 g) is passed through the packed column to adsorb latamoxef.
  • This column is washed with water (1360 ml) and then with 50% methanol (125 ml) to remove non-adsorbing contaminants (e.g., salts).
  • latamoxef is eluted with 70% methanol (535 ml).
  • the effluents contain the objective material at a concentration of 0.5% when estimated ultraviolet spectrophotometerically.
  • a 0.19% crude latamoxef aqueous solution is adjusted pH to 2.9.
  • a nonionic macroporous polymeric adsorbent (Amberlite XAD-2000, a stylene-divinylbenzene copolymer resin produced by Rohm and Haas Co.) (100 ml) is packed in 255 mm height in a glass tube which has 22 mm inside diameter.
  • the said solution (4800 ml; containing 8.02 g of the said compound) is passed through the packed column to adsorb the objective material. This column is washed with water (2480 ml). Then purified objective material is eluted with 50 to 80% methanol (810 ml).
  • the effluents contain 68.7% of the feeding objective material when estimated ultra-violet spectrophotometrically.
  • a 0.94% crude latamoxef aqueous solution is adjusted pH to 2 to 3.
  • a nonionic macroporous polymeric adsorbent (Diaion SP-207, a stylene-divinylbenzene copolymer resin produced by Mitsubishi Chemical Industries Limited) (40 ml) is packed in 115 mm height in a glass tube which has 19 mm inside diameter.
  • the said solution (200 ml; containing 1.88 g of the said compound) is passed through the packed column to adsorb latamoxef. This column is washed with water (200 ml). Then the purified objective material is eluted with 50% acetone (220 ml).
  • the effluents contain 93.3% of the feed objective material when estimated from high precision liquid chromatogram.
  • the eluting solvent 50% acetone
  • 70% isopropanol can be replaced by 70% isopropanol to obtain the same pure product in high yield.
  • a 1.0% crude 7 ⁇ -difluoromethylthioacetamido-3-[1-(2-hydroxyethyl)tetrazol-5-yl]thiomethyl-7 ⁇ -methoxy-1-dethia-1-oxa-3-cephem-4-carboxylic acid aqueous solution is adjusted pH to about 2.
  • a nonionic macroporous polymeric adsorbent (Diaion SP-207, a stylene-divinylbenzene copolymer adsorbent resin produced by Mitsubishi Chemical Industries Limited) (40 ml) is packed in 105 mm height in a glass tube which has 22 mm inside diameter.
  • the solution (210 ml; containing 2.0 g of the said compound) is passed through the packed column to adsorb the objective material. This column is washed with water (100 ml). Then purified objective material is eluted with 70% isopropanol (140 ml).
  • the effluents contain 87.1% of the feeding objective material when estimated ultra-violet spectrophotometrically.
  • a 1.0% crude 7 ⁇ -difluoromethylthioacetamido-3-[1-(2-hydroxyethyl)tetrazol-5-yl]thiomethyl-7 ⁇ -methoxy-1-dethia-1-oxa-3-cephem-4-carboxylic acid aqueous solution is adjusted pH to about 2.
  • a nonionic macroporous polymeric adsorbent (Amberlite XAD-2000, a stylene-divinylbenzene copolymer adsorbent resin produced by Rohm and Haas Co.) (30 ml) is packed in 275 mm height in a glass tube which has 12 mm inside diameter.
  • the said solution (200 Ml; containing 2.0 g or the said compound) is passed through the packed column to adsorb the objective material. This column is washed with water (300 ml). Then purified objective material is eluted with 70% isopropanol (80 ml).
  • the effluents contain 99.4% of the feed objective material when estimated ultra-violet spectrophotometrically.
  • a nonionic macroporous polymeric adsorbent (Diaion SP-207, a stylene-divinylbenzene copolymer resin produced by Mitsubishi Chemical Industries Limited) (30 ml) is packed in 132 mm height in a glass tube which has 16 mm inside diameter.
  • the said solution (200 ml; containing 0.3 g of the said compound) is passed through the packed column to adsorb the objective material.
  • This column is washed with water (200 ml).
  • the purified objective material is eluted with 70% isopropanol (150 ml).
  • the effluents contain 77.5% of the feeding objective material when estimated ultra-violet spectrophotometrically.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

A process for purifying oxacephalosporins which comprises contacting an aqueous solution of oxacephalosporin carboxylic acid (at pH lower than its pKa) with a macroporous polymeric adsorbent (specific gravity: higher than 1.05; and saturated adsorption capacity for cephalosporin C. larger than 60 mg/ml) to adsorb and thereby separate the oxacephalosporin carboxylic acid from non-adsorbable contaminants, and then eluting the adsorbed oxacephalosporin carboxylic acid with an aqueous hydrophilic organic solvent to elute and thereby separate it from non-eluting contaminants.

Description

This invention relates to a process for purifying oxacephalosporins useful as antibacterials. More specifically, it relates to a process for purifying oxacephalosporin carboxylic acids which comprises contacting an aqueous solution of the oxacephalosporin carboxylic acid (at pH lower than its pKa) with a macroporous polymeric adsorbent (specific gravity: higher than 1.05; and saturated adsorption capacity for cephalosporin C: larger than 60 mg/ml, i.e., more than 1.2 times as high as adsorbents reported in the literature to separate non-adsorbable contaminants therefrom, and then eluting it with an aqueous hydrophilic organic solvent to separate from non-eluting contaminants therefrom.
In the production of oxacephalosporins, contaminants are removed by repeated extraction, precipitation, crystallization, adsorption by old type synthetic adsorbents (e.g., Amberlite XAD-2, XAD-4, XAD-7, XAD-8, Diaion HP-10, HP-20, HP-30, HP-40, and HP-50), elution, or the like in the work up.
The present inventors looked for a suitable method to promote efficiency of the purification and completed this invention for purifying it with a macroporous polymeric adsorbent (specific gravity: higher than 1.05; and saturated adsorption capacity for cephalosporin C: larger than 60 mg/ml, i.e., more than 1.2 times as high as adsorbent written in the citations).
It is known to use macroporous polymeric adsorbents to remove electro-neutral materials, low molecular weight substances, or the like from cephalosporin aqueous solutions [e.g., Japanese Patent Publication (Kokoku) SHO-52-50799, 54-16922; and Japanese Patent Application Publication (Kokai) SHO-50-106996, 51-110587, etc.]. However, the known methods have several defects (e.g., lower adsorption capacity of the resins, turbidity of eluted solvent, and difficulty of handling due to low specific gravity).
In contrast, the macroporous polymeric adsorbent of this invention (having specific gravity of higher than 1.05 and saturated adsorption capacity for cephalosporin C of larger than 60 mg/ml., i.e., more than 1.2 times as high as adsorbents written in the literatures) has no such defect, and it is suitable for purifying the unstable oxacephalosporin free carboxylic acids.
Typical nonionic macroporus polymeric adsorbents are Amberlite XAD-2000, a stylene divinylbenzene copolymer resin produced by Rohm and Haas Co., and Diaion SP-206 and SP-207, styrene divinylbenzene copolymer resins produced by Mitsubishi Chemical Industries Limited.
The oxacephalosporin to be purified by this invention is 1-dethia-1-oxa-3-cephem-4-carboxylic acid or its derivative having at least one carboxy and having acylamino at position 7β, hydrogen or methoxy at position 7α, and R or CH2 R group at position 3 (here, R is hydrogen, halogen, alkyl, carbamoyl, carboxy, hydroxy, alkoxy, acyloxy, alkylthio, haloalkylthio, arylthio, heterocyclic thio, pyridinium, substituted pyridinium, or the like nucleophilic group). The acyl in the acylamino is that of the amido side chain in the penicillin or cephalosporin chemistry. The heterocyclic group is mono- or di-cyclic heterocyclic group having one or more hetero atom selected from nitrogen, oxygen, and sulfur and optionally substituted by alkyl or R-substituted alkyl. The said parts may have R or other conventional substituent in the cephalosporin moiety.
The amount of the macroporous polymeric resin used in this invention (having specific gravity of higher than 1.05 and saturated adsorption capacity for cephalosporin C of larger than 60 mg/ml, i.e., more than 1.2 times as high as adsorbents written in the literatures) is preferably 5 to 100 times the weight of the feeding oxacephalosporin free carboxylic acid.
The concentration of the oxacephalosporin carboxylic acid is preferably 0.1 to 30 w/w %. Preferably, the solution contains no adsorption inhibiting substance (for example, an organic solvent) over the inihibiting concentration. The operating temperature is preferably 0° to 50° C.
Adsorption is effected by contacting the aqueous solution of oxacephalosporin with the said macroporous polymer adsorbent by a conventional method (e.g., batch method, column method, or chromatographic method).
In order to remove non-adsorbable materials from the adsorbed material, the resin on which oxacephalosporin has been adsorbed is washed with a liquid which can wash out the non-adsorbable contaminants without eluting the desired substance. Such liquid can be, for example, water, buffer solution, salt solution, aqueous surfactant solution, or the like. Here again, a conventional method (e.g., batch method, column method, chromatographic method, or gradient method) is applicable. The washing can be continued until no impurity detectable in the effluents from the resin. The preferable temperature is 0° to 50° C.
For eluting the adsorbed objective material, it is preferable to use an aqueous organic solvent (e.g., ester, ketone, alcohol, or ether, especially lower alkanol). This may contain a substance for controlling eluting efficiency or independent of eluting (e.g., inorganic salt, acid, base, or cation surfactant). This elution may be carried out in a conventional operation (e.g., batch method, column method, chromatographic method, or gradient method), preferably at 0° to 50° C. The eluting procedure is stopped when the objective material has been eluted and the non-eluting contaminants remain on the adsorbent.
The used adsorbent can be recovered for using again in a usual operation (with, e.g., aqueous sodium hydroxide, neutral or acidic methanol or isopropanol, or mixture of these).
The oxacephalosporin can be recovered from the effluents by a conventional operation (e.g., extraction, concentration, precipitation, crystallization, of lyophilization).
Each step of this invention can be carried out at room temperature or at 0° to 50° C. for 30 minutes to 50 hours.
The oxacephalosporin carboxylic acids produced by this invention with low energy consumption is highly pure and highly yielding.
The following examples illustrate embodiments of this invention.
EXAMPLE 1.
A 0.11% crude latamoxef sodium [i.e., 7β-(2-p-hydroxyphenyl-2-carboxyacetamido)-3-(1-methyltetrazol-5-yl]thiomethyl-7α-methoxy-1-dethia-1-dethia-1-oxa-3-cephem-4-carboxylic acid disodium salt] aqueous solution (produced by hydrolyzing latamoxef dibenzhydryl ester with aluminum chloride and by removing organic solvents from the reaction mixture) is adjusted pH to 1.5 with hydrochloric acid.
A nonionic macroporous polymeric adsorbent (Amberlite XAD-2000, a stylene-divinylbenzene copolymer adsorbent resin produced by Rohm and Haas Co.) (200 ml) is packed in 270 mm height in a glass tube which has 32 mm inside diameter and 350 mm length. The said solution (2780 g) is passed through the packed column to adsorb latamoxef. This column is washed with water (1360 ml) and then with 50% methanol (125 ml) to remove non-adsorbing contaminants (e.g., salts). Then, latamoxef is eluted with 70% methanol (535 ml). The effluents contain the objective material at a concentration of 0.5% when estimated ultraviolet spectrophotometerically.
The effluents are concentrated under diminished pressure, neutralized with aqueous sodium hydroxide, and lyophilized to obtain pure latamoxef sodium. Yield: 86%.
EXAMPLE 2.
A 0.19% crude latamoxef aqueous solution is adjusted pH to 2.9.
A nonionic macroporous polymeric adsorbent (Amberlite XAD-2000, a stylene-divinylbenzene copolymer resin produced by Rohm and Haas Co.) (100 ml) is packed in 255 mm height in a glass tube which has 22 mm inside diameter. The said solution (4800 ml; containing 8.02 g of the said compound) is passed through the packed column to adsorb the objective material. This column is washed with water (2480 ml). Then purified objective material is eluted with 50 to 80% methanol (810 ml). The effluents contain 68.7% of the feeding objective material when estimated ultra-violet spectrophotometrically.
EXAMPLE 3.
A 0.94% crude latamoxef aqueous solution is adjusted pH to 2 to 3.
A nonionic macroporous polymeric adsorbent (Diaion SP-207, a stylene-divinylbenzene copolymer resin produced by Mitsubishi Chemical Industries Limited) (40 ml) is packed in 115 mm height in a glass tube which has 19 mm inside diameter. The said solution (200 ml; containing 1.88 g of the said compound) is passed through the packed column to adsorb latamoxef. This column is washed with water (200 ml). Then the purified objective material is eluted with 50% acetone (220 ml). The effluents contain 93.3% of the feed objective material when estimated from high precision liquid chromatogram.
Similarly, the eluting solvent, 50% acetone, can be replaced by 70% isopropanol to obtain the same pure product in high yield.
EXAMPLE 4
A 1.0% crude 7β-difluoromethylthioacetamido-3-[1-(2-hydroxyethyl)tetrazol-5-yl]thiomethyl-7α-methoxy-1-dethia-1-oxa-3-cephem-4-carboxylic acid aqueous solution is adjusted pH to about 2.
A nonionic macroporous polymeric adsorbent (Diaion SP-207, a stylene-divinylbenzene copolymer adsorbent resin produced by Mitsubishi Chemical Industries Limited) (40 ml) is packed in 105 mm height in a glass tube which has 22 mm inside diameter. The solution (210 ml; containing 2.0 g of the said compound) is passed through the packed column to adsorb the objective material. This column is washed with water (100 ml). Then purified objective material is eluted with 70% isopropanol (140 ml). The effluents contain 87.1% of the feeding objective material when estimated ultra-violet spectrophotometrically.
EXAMPLE 5
A 1.0% crude 7β-difluoromethylthioacetamido-3-[1-(2-hydroxyethyl)tetrazol-5-yl]thiomethyl-7α-methoxy-1-dethia-1-oxa-3-cephem-4-carboxylic acid aqueous solution is adjusted pH to about 2.
A nonionic macroporous polymeric adsorbent (Amberlite XAD-2000, a stylene-divinylbenzene copolymer adsorbent resin produced by Rohm and Haas Co.) (30 ml) is packed in 275 mm height in a glass tube which has 12 mm inside diameter. The said solution (200 Ml; containing 2.0 g or the said compound) is passed through the packed column to adsorb the objective material. This column is washed with water (300 ml). Then purified objective material is eluted with 70% isopropanol (80 ml). The effluents contain 99.4% of the feed objective material when estimated ultra-violet spectrophotometrically.
EXAMPLE 6
A 0.15% crude 7β-[2-2-carbamoyl-2-fluorovinylthio)acetamido]-3-[1-(2-hydroxyethyl)tetrazol-5-yl]thiomethyl-7α-methoxy-1-dethia-1-oxa-3-cephem-4-carboxylic acid aqueous solution is adjusted pH to about 2.
A nonionic macroporous polymeric adsorbent (Diaion SP-207, a stylene-divinylbenzene copolymer resin produced by Mitsubishi Chemical Industries Limited) (30 ml) is packed in 132 mm height in a glass tube which has 16 mm inside diameter. The said solution (200 ml; containing 0.3 g of the said compound) is passed through the packed column to adsorb the objective material. This column is washed with water (200 ml). Then the purified objective material is eluted with 70% isopropanol (150 ml). The effluents contain 77.5% of the feeding objective material when estimated ultra-violet spectrophotometrically.

Claims (6)

What we claim is:
1. A process for purifying oxacephalosporins which comprises contacting an aqueous solution of oxacephalosporin carboxylic acid (at pH lower than its pKa) with a macroporous polymeric adsorbent (specific gravity is higher than 1.05; and saturated adsorption capacity for cephalosporin C is larger than 60 mg/ml) to adsorb and thereby separate the oxacephalsporin carboxylic acid from non-adsorbable contaminants, and then eluting the adsorbed oxacephalosporin carboxylic acid with an aqueous hydrophilic organic solvent to elute and thereby separate the oxacephalosporin carboxylic acid from non-eluting contaminants.
2. The process as claimed in claim 1 wherein the process is carried out at 0° to 50° C.
3. The process as claimed in claim 1 wherein the oxacephalosporin carboxylic acid is latamoxef, 7β-difluoromethylthioacetamido-3-[1-(2-hydroxyethyl)tetrazol-5-yl]thiomethyl-7α-methoxy-1-dethia-1-oxa-3-cephem-4-carboxylic acid, or 7β-[2-(2-carbamoyl-2-fluorovinylthio)acetamido]-3-[1-(2-hydroxyethyl)tetrazol-5-yl]thiomethyl-7α-methoxy-1-dethia-1-oxa-3-cephem-4-carboxylic acid.
4. The process as claimed in claim 1 wherein the macroporous polymeric adsorbent is Amberlite XAD-2000, Diaion SP-206, or Diaion SP-207.
5. The process as claimed in claim 1 wherein amount of the macroporous polymeric adsorbent is 5 to 100 times the weight of the aqueous solution of oxacephalosporin carboxylic acid.
6. The process as claimed in claim 1 wherein the eluting solvent is 50 to 80% methanol, ethanol, propanol, isopropanol, or acetone aqueous solution.
US06/696,430 1984-02-02 1985-01-30 Purification of cephalosporins Abandoned USH328H (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP59017699A JPS60161990A (en) 1984-02-02 1984-02-02 Method for purifying oxacephalosporin
JP59-17699 1984-02-02

Publications (1)

Publication Number Publication Date
USH328H true USH328H (en) 1987-09-01

Family

ID=11951038

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/696,430 Abandoned USH328H (en) 1984-02-02 1985-01-30 Purification of cephalosporins

Country Status (5)

Country Link
US (1) USH328H (en)
JP (1) JPS60161990A (en)
DE (1) DE3503303A1 (en)
FR (1) FR2559153B1 (en)
GB (1) GB2153823B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113549089A (en) * 2021-06-30 2021-10-26 海南海灵化学制药有限公司 Method for purifying latamoxef sodium

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101857601B (en) * 2010-06-13 2012-11-21 胡建荣 Latamoxef sodium compound with high purity
CN104497011B (en) * 2015-01-14 2016-03-02 芦红代 A kind of preparation method of Latamoxef Sodium

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE824028A (en) * 1974-01-23 1975-06-30 PROCESS FOR THE PURIFICATION OF CEPHALOSPORINS CONTAINING A FREE CARBOXYLIC ACID GROUP

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113549089A (en) * 2021-06-30 2021-10-26 海南海灵化学制药有限公司 Method for purifying latamoxef sodium

Also Published As

Publication number Publication date
FR2559153A1 (en) 1985-08-09
FR2559153B1 (en) 1986-12-12
DE3503303A1 (en) 1985-08-08
JPS60161990A (en) 1985-08-23
GB2153823B (en) 1987-10-21
GB8502560D0 (en) 1985-03-06
GB2153823A (en) 1985-08-29

Similar Documents

Publication Publication Date Title
RU2235098C2 (en) Method for preparing hmg-coa-reductase inhibitor of high purity degree
EP1612216B1 (en) Process of purifying vancomycin hydrochloride
HU197926B (en) Process for recovering glycopeptide antibiotics
PL81295B1 (en)
US3124576A (en) Hjn-ch-ch
USH328H (en) Purification of cephalosporins
US6730497B2 (en) Process for preparing cephalosporanic acid derivatives using β-ketoacid derivatives
KR890001010B1 (en) Process for the recovery and purification of ceftazidine
EP0428984B1 (en) Separation method of amino acids
US4028355A (en) Cephalosporin purification process
US3983108A (en) Antibiotic purification process
DE2502097A1 (en) METHOD FOR CLEANING UP CEPHALOSPORINES
US5854390A (en) Chromatographic purification of vancomycin hydrochloride by use of preparative HPLC
US4145539A (en) Process for isolation and purification of cephalosporin compound
CA1286285C (en) Stable hydrate of penicillin derivative and process for preparing same
EP0025233B1 (en) Method for purification of 6-(d-2-(d-2-amino-3-n-methylcarbamoylpropionamido)-2-p-hydroxyphenylacetamido)-penicillanic acid
US3522248A (en) Process for the isolation of cephalosporin c
US5516919A (en) Process for producing ascorbic acid derivative
JP2002509933A (en) A new method for fermentative production of cephalosporins
US2643210A (en) Vitamin b12-active substance elution from montmorillonite absorbent
US3824238A (en) Method for the purification of 7-amino-desacetoxycephalosporanic acid
JPH0124795B2 (en)
HU214452B (en) Process for producing salts of deferoxamin b with high purity
JP4919421B2 (en) Process for producing (R) -3-morpholine carboxylic acid
CS240385B1 (en) Cephaelotine salts cleaning method

Legal Events

Date Code Title Description
AS Assignment

Owner name: SHIONOGI & CO., LTD., FUKUSHIMA-KU, OSAKA, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:KOIZUMI, HIROAKI;KAWATAKE, SATORU;TOKUYAMA, KANJI;REEL/FRAME:004364/0300

Effective date: 19850118

STCF Information on status: patent grant

Free format text: PATENTED CASE